This medicine is now known as Angiotensin 1-7.
On 20 June 2017, orphan designation (EU/3/17/1879) was granted by the European Commission to Envigo Pharma Consulting Limited, United Kingdom, for Asp-Arg-Val-Tyr-Ile-His-Pro (also known as TXA127) for the treatment of epidermolysis bullosa.
The sponsorship was transferred to Envigo CRS S.A., Spain, in April 2019.
Asp-Arg-Val-Tyr-Ile-His-Pro (Angiotensin 1-7)
|Disease / condition||
Treatment of epidermolysis bullosa
|Date of first decision||
|EU designation number||
Review of designation
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
- European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
- Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;